Compare MRNA & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | ALGN |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 11.9B |
| IPO Year | 2018 | N/A |
| Metric | MRNA | ALGN |
|---|---|---|
| Price | $31.18 | $157.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 13 |
| Target Price | $33.25 | ★ $187.50 |
| AVG Volume (30 Days) | ★ 10.2M | 1.2M |
| Earning Date | 02-13-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.16 |
| Revenue | $2,232,000,000.00 | ★ $3,982,622,000.00 |
| Revenue This Year | N/A | $2.58 |
| Revenue Next Year | $2.17 | $3.36 |
| P/E Ratio | ★ N/A | $30.25 |
| Revenue Growth | N/A | ★ 0.56 |
| 52 Week Low | $22.28 | $122.00 |
| 52 Week High | $48.92 | $237.23 |
| Indicator | MRNA | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.34 | 52.05 |
| Support Level | $29.06 | $154.98 |
| Resistance Level | $31.25 | $159.16 |
| Average True Range (ATR) | 1.58 | 3.07 |
| MACD | -0.24 | -1.35 |
| Stochastic Oscillator | 31.77 | 6.19 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.